Faslomax

Fulvestrant is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.

Fulvestrant is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.

Fulvestrant is a selective estrogen receptor degrader (SERD) and was first in class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell’s normal protein degradation processes to destroy it.

 

INDICATIONS

Monotherapy

FASLOMAX is indicated for the treatment of:

  • hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or
  • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.

Combination Therapy with Palbociclib

FASLOMAX is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.

 

Generic Name Strength Standard Type Packing Pack Size
Fulvestrant 250 mg IP PFS Vial  1 Vial